Its application is reserved for a specific subgroup of high-risk CLL patients, defined by clinical and/or genetic resistance (TP53 abnormalities) to treatment with chemoimmunotherapy and unresponsiveness to pathway inhibitors [4]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.